ABVC BIOPHARMA, INC.

ABVC BioPharma is a clinical-stage biopharmaceutical company developing drugs and medical devices targeting unmet medical needs across oncology, psychiatry, ophthalmology, and hematology. The company's pipeline includes multiple candidates in Phase II trials, including ABV-1501 for triple negative breast cancer, ABV-1504 for depressive disorders, ABV-1505 for adult attention deficit hyperactivity disorder, ABV-1702 for myelodysplastic syndromes, and ABV-1703 for metastatic pancreatic cancer. Additional programs in earlier development stages include ABV-1601 for depression in cancer patients, ABV-1701 (Vitargus) for retinal detachment and vitreous hemorrhage, and ABV-1519 for non-small cell lung cancer. The company also develops ophthalmic solutions, including ABV-2001 intraocular irrigation solution and ABV-2002 corneal storage solution.

The company maintains co-development and collaboration agreements with external partners including Rgene Corporation, BioHopeKing Corporation, and BioFirst Corporation. ABVC BioPharma operates as a subsidiary of YuanGene Corporation. Based in Fremont, California, the company operates with a lean structure of 16 full-time employees and maintains operations primarily within the United States. As a clinical-stage entity without approved products, the company does not generate product revenue.